Analysis of Molecular Imaging Biomarkers Derived from [ 18 F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [ 225 Ac]Ac-PSMA-617-Augmented [ 177 Lu]Lu-PSMA-617 Radioligand Therapy.

Autor: Burgard, Caroline¹ (AUTHOR) caroline.burgard@uks.eu, Khreish, Fadi^1,2 (AUTHOR) s8lsdahl@stud.uni-saarland.de, Dahlmanns, Lukas¹ (AUTHOR) arne.blickle@uni-saarland.de, Blickle, Arne¹ (AUTHOR) moritz.bastian@uks.eu, Bastian, Moritz B.¹ (AUTHOR) tilman.speicher@uks.eu, Speicher, Tilman¹ (AUTHOR) stephan.maus@uks.eu, Maus, Stephan¹ (AUTHOR) andrea.schaefer@uks.eu, Schaefer-Schuler, Andrea¹ (AUTHOR) mark.bartholomae@uks.eu, Bartholomä, Mark¹ (AUTHOR) sven.petto@uks.eu, Petto, Sven¹ (AUTHOR) samer.ezziddin@uks.eu, Ezziddin, Samer¹ (AUTHOR) florian.rosar@uks.eu, Rosar, Florian¹ (AUTHOR)

Publikováno v: Cancers. Oct2024, Vol. 16 Issue 20, p3532. 12p.

Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval

Autor: Amir Karimzadeh, Charlotte-Sophie Hecker, Matthias M. Heck, Robert Tauber, Calogero D’Alessandria, Wolfgang A. Weber, Matthias Eiber, Isabel Rauscher

Publikováno v: EJNMMI Research, Vol 14, Iss 1, Pp 1-10 (2024)

Abstract Background The optimal regimen for 177Lu-labeled prostate-specific membrane antigen-targeted radioligand therapy, including treatment intervals, remains under study, with evidence suggesting shorter intervals could benefit patients with high

Externí odkaz: https://doaj.org/article/31e329c31e0949a1906aa3f3aad0cf6d

All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [¹⁷⁷Lu]Lu-PSMA-radioligand will be successful.

Autor: Bogsrud, Trond Velde^1,2 (AUTHOR) trond.bogsrud@unn.no, Engelsen, Ola¹ (AUTHOR), Lu, Thuy Thu Thi¹ (AUTHOR), Stensvold, Andreas³ (AUTHOR), Johnson, Derek R.⁴ (AUTHOR), Burkett, Brian J.⁴ (AUTHOR), Kendi, Ayse Tuba⁴ (AUTHOR), Pandey, Mukesh K.⁴ (AUTHOR), Sundset, Rune^1,5 (AUTHOR), Durski, Jolanta M.⁴ (AUTHOR)

Publikováno v: EJNMMI Research. 10/15/2024, Vol. 14 Issue 1, p1-6. 6p.

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [ ¹⁷⁷ Lu]Lu-PSMA-617 Radioligand Therapy.

Autor: Siripongsatian, Dheeratama¹ (AUTHOR), Jantarato, Attapon¹ (AUTHOR), Promteangtrong, Chetsadaporn¹ (AUTHOR), Kunawudhi, Anchisa¹ (AUTHOR), Kiatkittikul, Peerapon¹ (AUTHOR), Boonkawin, Natphimol¹ (AUTHOR), Yaset, Sukanya¹ (AUTHOR), Somboon, Sirinsuda¹ (AUTHOR), Chotipanich, Chanisa¹ (AUTHOR)

Publikováno v: Indian Journal of Radiology & Imaging. Oct2024, Vol. 34 Issue 4, p579-587. 9p.

Characterization of tritiated JNJ-GluN2B-5 (3-[ ³ H] 1-(azetidin-1-yl)-2-(6-(4-fluoro-3-methyl-phenyl)pyrrolo[3,2-b]pyridin-1-yl)ethanone), a high affinity GluN2B radioligand with selectivity over sigma receptors.

Autor: Schoellerman J; Neuroscience Discovery, Janssen Research & Development, LLC, La Jolla, California, USA., Lord B; Neuroscience Discovery, Janssen Research & Development, LLC, La Jolla, California, USA., Bhattacharya A; Neuroscience Discovery, Janssen Research & Development, LLC, La Jolla, California, USA., Stenne B; Neuroscience Discovery, Janssen Research & Development, LLC, La Jolla, California, USA., Wall JL; Neuroscience Discovery, Janssen Research & Development, LLC, La Jolla, California, USA., Rech J; Neuroscience Discovery, Janssen Research & Development, LLC, La Jolla, California, USA., Letavic M; Neuroscience Discovery, Janssen Research & Development, LLC, La Jolla, California, USA., Bonaventure P; Neuroscience Discovery, Janssen Research & Development, LLC, La Jolla, California, USA., Balana B; Neuroscience Discovery, Janssen Research & Development, LLC, La Jolla, California, USA.

Publikováno v: Journal of neurochemistry [J Neurochem] 2024 Sep; Vol. 168 (9), pp. 2654-2670. Date of Electronic Publication: 2024 May 21.